Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BIOX
BIOX logo

BIOX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Bioceres Crop Solutions Corp (BIOX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.370
1 Day change
-5.58%
52 Week Range
5.160
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the provided data, Bioceres Crop Solutions Corp (BIOX) does not present a strong buy opportunity for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no positive catalysts, financial data, or significant trading signals to support an immediate investment. It is advisable to monitor the stock for potential improvements in technical and fundamental conditions.

Technical Analysis

The technical indicators for BIOX are bearish. The MACD is negatively expanding below zero (-0.00354), indicating downward momentum. The RSI_6 is at 18.82, signaling an oversold condition, but this alone is not sufficient to confirm a reversal. Moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (S1: 0.381, S2: 0.36), with resistance levels at R1: 0.45 and R2: 0.472.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
5

Positive Catalysts

  • NULL identified. There are no recent news events, no significant hedge fund or insider activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The stock has experienced a significant regular market decline of -5.48% and continues to show bearish technical indicators. There is no recent news or event-driven catalyst to suggest a reversal in sentiment.

Financial Performance

No financial data available for analysis. The latest quarter's financials could not be assessed due to data unavailability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on recent analyst ratings or price target changes. Wall Street sentiment is unclear.

Wall Street analysts forecast BIOX stock price to rise
1 Analyst Rating
Wall Street analysts forecast BIOX stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 0.395
sliders
Low
2
Averages
2
High
2
Current: 0.395
sliders
Low
2
Averages
2
High
2
Canaccord
Austin Moeller
Hold
downgrade
$2
AI Analysis
2026-01-02
Reason
Canaccord
Austin Moeller
Price Target
$2
AI Analysis
2026-01-02
downgrade
Hold
Reason
Canaccord analyst Austin Moeller lowered the firm's price target on Bioceres to $2 from $2.25 and keeps a Hold rating on the shares. On December 18, New York's Supreme Court ruled against Bioceres in ongoing litigation with the company's creditors, the analyst tells investors in a research note. The firm says that with the judge's non-final verdict determined, a credit sale process of Bioceres' Pro Farm assets will likely now ensue. It believes the process could be damaging to the company's operations.
Canaccord
Hold
downgrade
2025-11-14
Reason
Canaccord
Price Target
2025-11-14
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Bioceres to $2.25 from $2.50 and keeps a Hold rating on the shares. The firm reported lower Q1 revenues and adjusted EBITDA. The company has executed well on management's previously stated business priorities, including efforts to improve the business's margin profile, reduce operating expenses and better manage WC. Management cited expectations for the sustained unwinding of the seed business to temporarily lower upfront revenue recognition for the next two quarters in the segment.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BIOX
Unlock Now

People Also Watch